Coegin Pharma

5.16 SEK

+5.31 %

Less than 1K followers

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+5.31 %

-15.13 %

-6.18 %

+44.13 %

+34.03 %

+33.33 %

-63.72 %

-74.27 %

-83.78 %

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Market cap

128.37M SEK

Turnover

85.62K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26/2

2026

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Regulatory press release11/20/2025, 1:50 PM

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Press release11/14/2025, 1:42 PM

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/6/2025, 1:45 PM

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Regulatory press release10/17/2025, 3:05 PM

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Press release10/13/2025, 8:02 AM

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Regulatory press release9/17/2025, 12:30 PM

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Regulatory press release9/10/2025, 1:00 PM

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Regulatory press release8/21/2025, 12:30 PM

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Press release8/20/2025, 6:30 AM

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma changes language for company communication to English

Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma ändrar språk för informationsgivning till engelska

Press release7/2/2025, 6:30 AM

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Press release7/2/2025, 6:30 AM

Coegin Pharma har sänkt produktkostnaden med 80 procent - närmar sig lansering av Follicopeptide

Regulatory press release5/22/2025, 11:30 AM

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Regulatory press release5/22/2025, 11:30 AM

Kommuniké från årsstämma i Coegin Pharma AB (publ)

Regulatory press release5/22/2025, 6:35 AM

Coegin Pharma AB publishes its quarterly report for the first quarter of 2025

Regulatory press release5/22/2025, 6:35 AM

Coegin Pharma AB (publ) publicerar delårsrapport för första kvartalet 2025

Regulatory press release4/29/2025, 10:45 AM

Coegin Pharma AB publishes Annual Report for the financial year 2024

Regulatory press release4/29/2025, 10:45 AM

Coegin Pharma publicerar årsredovisning för räkenskapsåret 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.